Importance of complete pathologic response to prehepatectomy chemotherapy in treating colorectal cancer metastases

Annals of Surgery

Volumn 250, Issue 6, 2009, Pages 935-942

  Tanaka, Kuniya ^a   Takakura, Hideki ^a   Takeda, Kazuhisa ^a   Matsuo, Kenichi ^a   Nagano, Yasuhiko ^a   Endo, Itaru ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MICROWAVE THERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PREOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 73449131515     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181b0c6e4     Document Type: Article

References (34)

1. Ho WM, Ma B, Mok T, et al. Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group. Med Oncol. 2005;22:303-312.
2. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18: 136-147.
3. Masi G, Cupini S, Marcucci L, et al. Treatment with 5-fluorouracil/ folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol. 2006;13:58-65.
4. Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol. 2004;15:933-939.
5. Alberts SR, Horvath WL, Sternfeld WC, et al; North Central Cancer Treatment Group phase II study. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer. J Clin Oncol. 2005;23:9243-9249.
6. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644-658.
7. Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006;24: 3939-3945.
8. Elias D, Youssef O, Sideris L, et al. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol. 2004;86:4-9.
9. Adam R, Wicherts DA, de Haas RJ, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol. 2008;26:1635-1641.
10. Yamanaka N, Okamoto E, Oriyama T, et al. A prediction scoring system to select the surgical treatment of liver cancer. Further refinement based on 10 years of use. Ann Surg. 1994;219:342-346.
11. Lévi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet. 1997;350:681-686. (Pubitemid 27371165)
12. Lévi F. Circadian chronotherapy for human cancers. Lancet Oncol. 2001;2: 307-315.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216. (Pubitemid 30099779)
14. van Ooijen B, Oudkerk M, Schmitz PI, et al. Detection of liver metastases from colorectal carcinoma: is there a place for routine computed tomography arteriography? Surgery. 1996;119:511-516.
15. Lencioni R, Donati F, Cioni D, et al. Detection of colorectal liver metastases: prospective comparison of unenhanced and ferumoxides-enhanced magnetic resonance imaging at 1. 5 T, dual-phase spiral CT, and spiral CT during arterial portography. MAGMA. 1998;7:76-87.
16. Kemeny N, Daly J, Reichman B, et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma: a randomized trial. Ann Intern Med. 1987;107:459-465. (Pubitemid 17149758)
17. Chang AE, Schneider PD, Sugarbaker PH, et al. A prospective randomized trial of regional versus systemic continuous 5-Fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg. 1987;206:685-693.
18. Martin JK, O'Connell MJ, Wieand HS, et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer: a randomized trial. Arch Surg. 1990;125:1022-1027.
19. Lorenz M, Müller H, Schramm H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. Ann Surg. 1998;228: 756-764.
20. Onaitis M, Morse M, Hurwitz H, et al. Adjuvant hepatic arterial chemotherapy following metastasectomy in patients with isolated liver metastases. Ann Surg. 2003;237:782-789.
21. Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colo-rectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18:299-304.
22. Buyse M, Thirion P, Carlson RW, et al; Meta-Analysis Group in Cancer. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Lancet. 2000;356:373-378.
23. Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy. A contraindication to liver resection for multiple colorectal metas-tases? Ann Surg. 2004;240:1052-1064.
24. Eilber FC, Rosen G, Eckardt J, et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol. 2001; 19:3203-3209.
25. Bertheau P, Lerebours F, Mounier N, et al. Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer. Oncol Rep. 2005;14:513-520.
26. Bramwell VH. The role of chemotherapy in the management of non-meta-static operable extremity osteosarcoma. Semin Oncol. 1997;24:561-571.
27. Tanaka K, Shimada H, Kubota K, et al. Effectiveness of prehepatectomy intra-arterial chemotherapy for multiple bilobar colorectal cancer metastases to the liver: a clinicopathologic study of peritumoral vasculobiliary invasion. Surgery. 2005;137:156-164.
28. Yokoyama N, Shirai Y, Ajioka Y, et al. Immunohistochemically-detected hepatic micrometastases predict a high risk of intrahepatic recurrence after resection of colorectal carcinoma liver metastases. Cancer. 2002;94:1642-1647.
29. Harun N, Nikfarjam M, Muralidharan V, et al. Liver regeneration stimulates tumor metastases. J Surg Res. 2007;138:284-290.
30. Dy GK, Krook JE, Green EM, et al. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. J Clin Oncol. 2007;25:3469-3474.
31. Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresect-able colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005;16:1311-1319.
32. Schott AF, Roubidoux MA, Helvie MA, et al. Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoad-juvant chemotherapy. Breast Cancer Res Treat. 2005;92:231-238.
33. Bertheau P, Lerebours F, Mounier N, et al. Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer. Oncol Rep. 2005;14:513-520.
34. Tan MC, Linehan DC, Hawkins WG, et al. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg. 2007;11:1112-1119.